Novo Nordisk A/S
We are a global healthcare company, founded in 1923 and headquartered just outside Copenhagen, Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity, and rare blood and rare endocrine diseases. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure the diseases we treat. We employ more than 47,000 people in 80 offices around the world, and market our products in 168 countries.
Find locations served, office locations
- Business Type:
- Industry Type:
- Medical Equipment
- Market Focus:
- Globally (various continents)
- Year Founded:
- Over 1000
Facts & Figures
production sites in nine countries (Algeria, Brazil, China, Denmark, France, Japan, Russia, UK and US).
research and development centres in five countries (China, Denmark, India, UK and US).
employees around the world.
number of countries we provide access to our products.
We will not allow the success of our company to be defined by the steady increase in the number of people living with serious chronic diseases, like type 2 diabetes and obesity.
We take no pleasure in the suffering and hardships faced by people living with a chronic disease. In some countries, the financial burden of providing or getting access to medical care puts people at risk of serious health complications.
We are committed to helping societies defeat diabetes, and our strategy is clear – accelerate prevention of type 2 diabetes and obesity, and provide access to affordable care for vulnerable patients in every country.
Our success will be defined by the solutions we bring and the health and well-being of the people and communities benefiting from them.
We are the first pharmaceutical company to use 100% renewable power in all our global production facilities. We are proud but also motivated to go even further.
With our Circular for Zero strategy, we are starting a journey to achieve zero environmental impact in all our business activities.
We will collaborate proactively with suppliers to reduce the environmental impact across our supply chain, cut CO2 emissions from all our operations and transportation, and solve the end-of-life product waste challenge to eliminate waste.
The Novo Nordisk Way
The Novo Nordisk Way is a set of guiding principles which underpins every decision we make. It describes who we are, how we work and what we want to achieve, and sets a clear direction for our company and our employees. Ultimately, it’s a promise we make to each other - and to the millions of patients all over the world who rely on our products to lead full and healthy lives.
In 1923, our Danish founders began a journey to change diabetes. Today, we are thousands of employees across the world with the passion, skills and commitment to drive change to defeat diabetes and other serious chronic diseases.
- We aim to lead in all disease areas in which we are active.
- Our key contribution is to discover and develop innovative biological medicines and make them accessible to patients throughout the world.
- Growing our business and delivering competitive financial results is what allows us to help patients live better lives, offer an attractive return to our shareholders and contribute to our communities.
- Our business philosophy is one of balancing financial, social and environmental considerations - we call it 'The Triple Bottom Line'.
- We are open and honest, ambitious and accountable, and treat everyone with respect.
- We offer opportunities for our people to realise their potential.
- We never compromise on quality and business ethics.
Every day, we must make difficult choices, always keeping in mind what is best for patients, our employees and our shareholders in the long run.
It's our way. It's the Novo Nordisk Way.
What we do
Discovering, developing and delivering
For almost 100 years, we have been translating the unmet medical needs of people living with a serious chronic disease into innovative medicines and delivery systems, like our insulin pens.
Our treatments today are benefiting millions of people living with diabetes, obesity, and rare blood and endocrine diseases.
From our labs to our factory floors, we are discovering and developing innovative biological medicines and making them accessible to patients throughout the world.